Matthew Barcus
Stock Analyst at Chardan Capital
(2.47)
# 2,462
Out of 5,008 analysts
21
Total ratings
25%
Success rate
28.89%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Barcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Buy | $12 → $10 | $3.99 | +150.63% | 3 | Mar 26, 2025 | |
| QURE uniQure | Maintains: Buy | $45 → $27 | $57.92 | -53.38% | 4 | Jun 22, 2023 | |
| XLO Xilio Therapeutics | Reiterates: Buy | $7 | $0.82 | +751.27% | 3 | May 30, 2023 | |
| IMVT Immunovant | Maintains: Buy | $21 → $32 | $16.11 | +98.63% | 4 | May 23, 2023 | |
| PPBT Purple Biotech | Reiterates: Buy | $220 | $0.58 | +37,778.79% | 3 | May 17, 2023 | |
| ANIX Anixa Biosciences | Reiterates: Buy | $9 | $4.11 | +118.98% | 3 | Apr 18, 2023 | |
| IMNM Immunome | Maintains: Buy | $9 → $8 | $13.82 | -42.11% | 1 | Mar 17, 2023 |
Zura Bio
Mar 26, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $3.99
Upside: +150.63%
uniQure
Jun 22, 2023
Maintains: Buy
Price Target: $45 → $27
Current: $57.92
Upside: -53.38%
Xilio Therapeutics
May 30, 2023
Reiterates: Buy
Price Target: $7
Current: $0.82
Upside: +751.27%
Immunovant
May 23, 2023
Maintains: Buy
Price Target: $21 → $32
Current: $16.11
Upside: +98.63%
Purple Biotech
May 17, 2023
Reiterates: Buy
Price Target: $220
Current: $0.58
Upside: +37,778.79%
Anixa Biosciences
Apr 18, 2023
Reiterates: Buy
Price Target: $9
Current: $4.11
Upside: +118.98%
Immunome
Mar 17, 2023
Maintains: Buy
Price Target: $9 → $8
Current: $13.82
Upside: -42.11%